Global Sources
EE Times-India
Stay in touch with EE Times India
EE Times-India > Manufacturing/Packaging

Agilent, Signature sign supply deal

Posted: 19 May 2008     Print Version  Bookmark and Share

Keywords:microarray  oligonucleotide 

Agilent Technologies Inc. and Signature Genomic Laboratories LLC announced their signing of a long-term supply agreement, wherein Agilent will supply custom oligonucleotide microarrays to Signature and Signature-designed SignatureChip Oligo Solution (SignatureChipOS) customers. The terms of the agreement were not disclosed.

The SignatureChipOS is designed for the detection of chromosome abnormalities in individuals with mental retardation/developmental delay, autism and congenital anomalies. The 105,000-feature, 60-mer microarray covers more than 150 syndromes, the subtelomeric and pericentromeric regions, and more than 500 genes in important developmental pathways.

"We're very pleased about this agreement, which is the latest example of how the marketplace is recognising the value of our highly flexible, high-quality custom oligonucleotide microarray production capability," said Yvonne Linney, Ph.D., Agilent vice president and general manager, Genomics. "We're delighted to work with Signature Genomic Laboratories, which specialises in microarray technology and is an innovative leader in microarray testing."

"We are committed to giving our customers the best services and technology available, and this agreement reflects this focus," said Lisa G. Shaffer, Ph.D., president and CEO of Signature. "Oligo arrays have improved dramatically in the past few years, and we are delighted there are now oligos that meet our high standards. This supply agreement also allows our Genoglyphix customers the opportunity to use high-quality oligo arrays for research applications in their laboratories."

Comment on "Agilent, Signature sign supply deal"
*  You can enter [0] more charecters.
*Verify code:


Visit Asia Webinars to learn about the latest in technology and get practical design tips.


Go to top             Connect on Facebook      Follow us on Twitter      Follow us on Orkut

Back to Top